My grandfather has just started taking Poly-MVA and though expensive it is promising. here is some information on it. I hope it helps you with whatever it is you need it for. Also In my research I have found it is promotional to overall health. Its beneficial to healthy cells. Harmful to cancer cells. When we had our consulation with our Dr. he said it contains a mineral called Pallium that is worth more than platnium(hence the high price's). But there is zero chance of Metal poisoning due to the way that Pallium is bound with alpha-lipoic acid. The other substance in Poly-MVA. The bond is so strong it cant break free. And also, Pallium is attracted to cancer cells and the way it interacts with the cancer( any type) makes the Cancer kill itself. And I repeat. No harm to healthy cells. It can also breach the Blood-Brain Barrier which is very hard to penetrate so it can get into Brain Cancers as well. It is both water and fat soluble meaning it can go anywhere and everywhere in the body. Here's my information and their sources.
http://www.townsendletter.com/FebMar_2003/polymva0203.htm
Recognized Poly-MVA Therapeutic Benefits
From the established therapeutic effects of its alpha lipoic acid/palladium complex, Poly-MVA provides at least 13 recognized anticancer benefits. The benefits are reproduced here from observations described by Dr. Merrill Garnett in a series of reports published on his animal studies conducted at the Garnett McKeen Laboratory in Islip, New York. One by one over time, he has advised that the lipoic acid/palladium complex (LAPd) does the following:8
1. LAPd causes an indefinite variety of immune system responses, but with specific manifestations as indicated in the twelve additional attributes listed below.
2. LAPd seeks out and destroys cancer cells anywhere in the body by stealing their electromagnetic energy.
3. LAPd invigorates normal cells and helps to repair any damage the invasive cancer may have left behind.
4. LAPd reduces tumor size or causes the tumor to shink.
5. LAPd produces an idiosyncratic set of effects which include a pattern of lag-arrest-slow death of cancer cells from an inhibition of their energy metabolism.
6. LAPd prevents sterol biosynthesis, thereby preventing new cancer cell plasma membrane synthesis.
7. LAPd shows a very large fraction of sensitive cancer cells as a morphological feature.
8. LAPd promotes the growth of proliferating normal cells surrounding a core of central tumor necrosis consisting of dead cancer cells.
9. LAPd stimulates the infiltration of leukocytes for the removal of cancer cell debris.
10. LAPd has absolutely no toxic reaction – no adverse side effects.
11. LAPd accomplishes its therapeutic benefits in both animals and humans.
12. LAPd works against cancer of many types not only as an orally administered liquid but also perhaps even more effectively as an intravenous injection.
13. LAPd reduces the incidence of cachexia with a potential for increased body weight of the frail cancer patient.
Being aware of the LAPd actions in Poly-MVA, Robert D. Milne, MD, Medical Director of the Milne Medical Center in Las Vegas, Nevada, has employed the metallovitamin complex for a family member and for the adjunctive nutritional healing of cancer in numbers of patients. He does not treat cancer but offers his patients nutritional support for their cancer. Poly-MVA is one of the more vital nutrients that Dr. Milne recommends.
"After undergoing a full oncological evaluation, my father-in-law at age 69 asked me to help him with a potentially deadly 14-cm by 2.5 cm-size Stage 3 transitional cell carcinoma of the bladder producing right-ureter obstruction," explains Dr. Milne. "Hospitalized in a critical care unit for ten days with acute respiratory distress syndrome from his adverse reaction to chemotherapy, my father-in-law was no longer a candidate for cytotoxic therapy. Upon my educating him about Poly-MVA, he undertook a therapeutic trial of this nutritional agent. With the Poly-MVA, I also recommended that he take 500 mg daily of coenzyme Q10 and 25 tablets daily of pancreatic enzymes. The treatment proved successful for him.
"His original tumor biopsy taken July 2001 was reported by the pathologist as 'invasive carcinoma Grade 2 with invasion into the muscularis propria.' Using just the nutritional program I had recommended," says Dr. Milne, "a report on the six-month followup biopsy of my father-in-law's tumor on January 11, 2002 stated, 'There is no cancer.' And his CAT scan showed, 'No evidence of the tumor in this patient's bladder.'
"I believe that the Poly-MVA adjunct for this patient was exceedingly helpful, and the work of Dr. Merrill Garnett is truly remarkable. It's different from any other therapy that has ever been done against cancer," says Dr. Robert D. Milne. "Based on my father-in-law's excellent result and the results experienced by many others, I truly believe that Poly-MVA is worth trying by any person who has cancer or wants to prevent its onset."
http://www.polymvasurvivors.com/
http://www.polymvasurvivors.com/ testimonials.html (Testimonials written by the survivors. 17 diffrent types of cancer in these testemonials ranging from Brain to Colon)
The substance in Poly-MVA called Palladium is a heavy metal. But the way it is bound to Lipoic Acid that is in Poly-MVA prevents it from seeping into the body. Basically this means the chance of anyone taking it(i.e. your Dad and my Grandpa) is Zero. Chemotherapy also has nowhere near the success rate of Poly-MVA nor does radiation treatment.
Source: http://www.annieappleseedproject.org/repfromconth.html
(read everthing in it. Important)
Clinical Studies
The first report of clinical studies of PolyMVA was presented by the late Rudolf E. Falk, an oncological surgeon at the University of Toronto, in March 1994. Dr. Falk reported that the compound was administered intravenously, subcutaneously (under the skin) and per Os in a modified phase 2 study. To quote from Dr. Falk's summary, "95 patients were treated; these included breast, lung, colorectal, prostate, pancreatic, ovarian, malignant melanoma and primary brain neoplasia. 90% of the patients were in the category of having failed all available therapy. 88 are surviving on therapy with a mean survival time of 9 months. The anticipated survival time of this group, from available statistics would vary from 20% to 60% at 6 months. All of these patients received moderate doses of chemotherapy."
The first 27 patients given PolyMVA were all considered terminal, and all refused to continue with chemotherapy. They were placed on a "health promotion program" as outlined in The Definitive Guide to Cancer, Chapter 23. The cancers involved brain, tongue, esophagus, lung, breast, stomach, colon, pancreas, prostate, lymph, blood, and marrow. All had metastasis. All were given 5 drops four times daily as a loading dose. 13 reported improvements in either appetite, weight gain, increased energy or reduction in pain within the first 7 days of starting PolyMVA. At the end of 14 days 6 additional patients reported improvement. None of the 27 patients reported adverse reactions.
We learned from this small study (1) that the initiating dose was inadequate, (2) rapid improvements can be expected in over 60% of patients with a variety of malignant conditions, and (3) PolyMVA is non-toxic. With this low dose, some patients demonstrated clinical changes indicating early improvement. A few anecdotal reports follow:
75 year old female with glioblastoma presented with history of debulking surgeries and 2 rounds of radiation. As a last resort her cancer center neurologist placed her on massive, experimental doses of tomoxifen. She entered the hospital in Baja California requiring support on both arms to walk up the short ramp. Her memory was impaired, she had slurred speech. Convulsions were under control with dilantin. On the 3rd day after beginning PolyMVA her memory had improved as had her slurred speech. She walked out of the hospital unaided to continue therapy at home. She lived 6 months. Her immediate death is attributable to the side effects of the tamoxifen which she continued to take before and after the PolyMVA.
Glioblastoma patients usually have a dramatic, early response similar to Mr. D. age 66. His tumor inactivated his right leg and foot and caused generalized convulsions which were poorly controlled by tegretol, or dilantin. I received a phone call from Mr. D. four days after he began PolyMVA. He said his paralysis was gone and he could walk outside and water the lawn and ride his stationary bicycle. Eight days after beginning he called again to report that his convulsions were now localized and almost gone.
Pain from metastatic breast cancer to the spine and right hip in CF age 56 required a right hip replacement which gave relief from hip pain, but did not effect the spine. She started PolyMVA and within 2 weeks her "back pain stopped" and she returned to her legal research employment. Most breast cancer patients report at least temporary improvement.
Two cases of cancer of esophagus requiring MS for pain relief, cachectic and terminal when they started PolyMVA. Mr. G. age 62 was in a Mexican hospital when he was scheduled to began the PolyMVA. LS age 45 took the PolyMVA for home use. Mr. G died within 6 weeks, but an investigation uncovered the fact hat he was never given the PolyMVA. He was given Laetril alone. LS reported increased strength and weight gain and is still living (2 years from starting PolyMVA).
Diagnosed in April 1995 a female multiple myeloma patient from Alaska with two degrees, a Ph.D. and J.D. sent us a letter dated March 1997 that after taking PolyMVA her blood tests and examinations showed " no measurable signs of multiple myeloma carcinoma" and her doctors said "She is in total remission."
Colon cancer patients with obstruction reported improvement using the PolyMVA by enema. This is logical since PolyMVA is soluable in fat and liquid.
Source: http://altmedangel.com/polymva.htm